Focalis Bio
PrivateLast Round
Series A
Dec 10, 2025
Total Funding Raised
$43M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Focalis Bio operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A round in December 2025.
Focalis Bio is a biotechnology company developing precision gene therapies to treat focal refractory epilepsy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Focalis Bio Comparables
Compare Focalis Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| COMBIGENE AB O.N. | 81% | |
| Encoded Therapeutics | 77% | |
| Latus Bio | 77% |
For institutional investors. Book with your work email.
Focalis Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 10, 2025 | ||||
| Seed | Jun 24, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Focalis Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| XGEN Venture | Series A |
| British Business Bank | Series A |
| Albion Capital | Seed |
| Zcube | Seed |
| Health Technology Holding | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 10, 2025
$33M round with XGEN Venture and British Business Bank.
- Jun 24, 2024
$10M raised, led by Albion Capital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 4, 2026
Focalis Bio is developing gene therapies for epilepsy in United Kingdom.
For institutional investors. Book with your work email.
Focalis Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Focalis Bio's valuation, stock price, and market status.
Is Focalis Bio a public or private company?
Focalis Bio is a private company.
What is the current stock price of Focalis Bio?
Focalis Bio is a private company, so its shares have no public market price. Caplight tracks Focalis Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Focalis Bio worth (valuation)?
Valuation information for Focalis Bio is not publicly available.
Can I buy Focalis Bio stock?
Focalis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Focalis Bio's last funding round?
Focalis Bio's most recent funding round was Series A on December 10, 2025.
Who are the main investors in Focalis Bio?
Key investors in Focalis Bio include Albion Capital.
Will Focalis Bio IPO soon?
No public IPO plans have been announced for Focalis Bio.
How can I track Focalis Bio secondary market activity?
Caplight tracks bids, offers, and trades in Focalis Bio's shares on secondary markets.